SCHEMBL4826466

SCHEMBL4826466

COc1cc(-c2nn(C3CCNCC3)c3ncnc(N)c23)ccc1NC(=O)c1ccc(Oc2ccccc2)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 19/20 0.70
SRC P12931 10/20 0.70
TEK Q02763 7/20 0.70
KDR P35968 3/20 0.59
FYN P06241 2/20 0.58
LIMK1 P53667 2/20 0.57
LIMK2 P53671 1/20 0.57
LYN P07948 2/20 0.56
BTK Q06187 1/20 0.56
ABL1 P00519 2/20 0.56
EGFR P00533 2/20 0.56
HCK P08631 2/20 0.56
PLK4 O00444 1/20 0.56
AURKA O14965 1/20 0.56
PAK4 O96013 1/20 0.56
CHEK2 O96017 1/20 0.56
ERBB2 P04626 1/20 0.56
NTRK1 P04629 1/20 0.56
INSR P06213 1/20 0.56
CSF1R P07333 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4826588 0.93 LCK (0.72) LCKSRCTEKKDRFYN
SCHEMBL4828065 0.93 LCK (0.74) LCKSRCTEKKDRFYN
Acetic Acid SCHEMBL4818363 0.93 LCK (0.76) LCKSRCTEKKDRFYN
SCHEMBL4828143 0.92 LCK (0.72) LCKSRCTEKKDRFYN
Acetic Acid SCHEMBL7702398 0.90 LCK (0.70) LCKSRCTEKKDRFYN
SCHEMBL4826959 0.90 LCK (0.72) LCKSRCTEKKDRFYN
SCHEMBL4828012 0.90 LCK (0.76) LCKSRCTEKKDRFYN
SCHEMBL4826334 0.90 LCK (0.72) LCKSRCTEKKDRFYN
Acetic Acid SCHEMBL6433451 0.90 LCK (0.66) LCKSRCTEKKDRABL1
SCHEMBL4869339 0.90 LCK (0.68) LCKSRCTEKKDRFYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7332497-B2 As inhibitors of protein kinases ABBOTT GMBH & CO KG (DE) 2008-02-19 US disclosed
US-6921763-B2 Pyrazolopyrimidines as therapeutic agents ABBOTT LABORATORIES (US) 2005-07-26 US disclosed
US-20050008640-A1 Method of treating transplant rejection ABBOTT LABORATORIES 2005-01-13 US disclosed
US-20040006083-A1 Pyrazolopyrimidines as therapeutic agents ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2004-01-08 US disclosed
US-20020156081-A1 Pyrazolopyrimidines as therapeutic agents ABBOTT LABORATORIES (US) 2002-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050008640-A1 Method of treating transplant rejection LCK, ZAP70, FYN LCK 1/4885SRC 46/4885TEK 1465/4885
US-20040006083-A1 Pyrazolopyrimidines as therapeutic agents DPYD, UGT1A1, ABCB1 LCK 1534/4885SRC 2167/4885TEK 1218/4885
US-20020156081-A1 Pyrazolopyrimidines as therapeutic agents DPYD, CYP2D6, UGT1A1 LCK 1011/4885SRC 1834/4885TEK 1657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.